Related Experiment Video
Updated: Aug 4, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
[Therapy concepts for thyroid carcinoma]
Friederike Eilsberger1, Michael C Kreissl2, Markus Luster3
1Klinik für Nuklearmedizin, Universitätsklinikum Marburg, Marburg, Germany.
Abstract:
Theranostics via the sodium iodide symporter (NIS) offer a unique option in differentiated thyroid carcinoma. The diagnostic and therapeutic nuclides have similar uptake and kinetics, making the NIS the most important theranostic target in this disease. Radioiodine refractory thyroid carcinomas (RRTC) are characterised by reduced/absent NIS expression, thus eliminating this structure as a theranostic target. Also due to limited therapeutic options, there are approaches to generate new theranostic targets in RRTC, via the expression of somatostatin receptors (SSTR) or the prostate-specific membrane antigen (PSMA), but the current evidence does not yet allow a final evaluation of the prospects of success.
Insights
Theranostics targeting the sodium iodide symporter (NIS) are effective for differentiated thyroid cancer. However, radioiodine-refractory thyroid carcinomas (RRTC) lack NIS, necessitating novel theranostic targets for improved treatment outcomes.
Area of Science:
- Oncology
- Nuclear Medicine
- Molecular Imaging
Context:
- Differentiated thyroid carcinoma (DTC) management relies on sodium iodide symporter (NIS) theranostics.
- Radioiodine-refractory thyroid carcinomas (RRTC) present a therapeutic challenge due to absent NIS expression.
- Limited treatment options for RRTC necessitate the development of alternative theranostic strategies.
Purpose:
- To explore the potential of novel theranostic targets in NIS-negative RRTC.
- To evaluate the feasibility of targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) in RRTC.
- To assess the current evidence for emerging theranostic approaches in advanced thyroid cancer.
Summary:
- The sodium iodide symporter (NIS) is a key theranostic target in differentiated thyroid carcinoma.
- Radioiodine-refractory thyroid carcinomas (RRTC) are characterized by reduced or absent NIS expression, rendering standard theranostics ineffective.
- Emerging strategies involve targeting alternative receptors like somatostatin receptors (SSTR) or prostate-specific membrane antigen (PSMA) in RRTC, though further evaluation is required.
Impact:
- This research highlights the limitations of current theranostics in RRTC.
- It identifies potential new theranostic targets for a challenging subset of thyroid cancer.
- Further investigation into SSTR and PSMA targeting could lead to improved therapeutic outcomes for patients with RRTC.
Related Concept Videos
The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Targeted Cancer Therapies
There are several types of targeted therapies against...

